Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moderna, Inc.

26.11
-0.3100-1.17%
Volume:3.45M
Turnover:91.00M
Market Cap:10.20B
PE:-3.24
High:26.85
Open:26.07
Low:25.97
Close:26.41
52wk High:48.92
52wk Low:23.04
Shares:390.68M
Float Shares:363.29M
Volume Ratio:1.09
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.0516
EPS(LYR):-9.2734
ROE:-29.32%
ROA:-15.49%
PB:1.09
PE(LYR):-2.82

Loading ...

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

Reuters
·
Oct 21

US Stocks Update | Moderna (MRNA.US) Rises Over 7% on Positive Data for Two New mRNA Vaccines

Stock News
·
Oct 20

Moderately bullish activity in Moderna with shares up 7.5%

TIPRANKS
·
Oct 20

Moderna Reports Positive Results for mRNA Flu Vaccines in Clinical Trials

Reuters
·
Oct 20

Stock Track | Moderna Soars 5% as Government Renews COVID-19 Immunization Strategy

Stock Track
·
Oct 20

Oppenheimer Reaffirms Their Hold Rating on Moderna (MRNA)

TIPRANKS
·
Oct 20

Hold Rating on Moderna’s mRNA-4359: Promising Early Data but Awaiting Further Validation

TIPRANKS
·
Oct 20

Stock Market Today: S&P 500, Nasdaq, Dow Jones Futures Rise— Micron, Bitmine, Coinbase In Focus

Benzinga
·
Oct 20

Moderna announces data on flu, pandemic flu candidates at IDWeek 2025

TIPRANKS
·
Oct 19

How Moderna's (MRNA) mRNA-4359 Cancer Vaccine Data Is Shaping Its Pipeline Diversification Narrative

Simply Wall St.
·
Oct 19

Moderna Inc. Stock Slides 4.2%, Underperforms Peers

Dow Jones
·
Oct 18

Moderna Shares Fall After Early Trial Update on mRNA-4359 Cancer Vaccine Combination

MT Newswires Live
·
Oct 18

Stock Track | Moderna Plummets 5% as Oncology Drug Update Disappoints Investors

Stock Track
·
Oct 18

Stock Track | Moderna Plummets 5% Following Oncology Update on mRNA-4359 Study

Stock Track
·
Oct 18

Moderna ‘checking another mark’ in oncology franchise, says Wolfe Research

TIPRANKS
·
Oct 18

Moderna Inc Shares Down 4.3% at $25.96

THOMSON REUTERS
·
Oct 18

Moderna sees 5-year follow up from Phase 2 study in 2026

TIPRANKS
·
Oct 18

Moderna down 4.2% after publishing results on mRNA-4359 plus pembrolizumab

TIPRANKS
·
Oct 18

Moderna Inc. Publishes Trial Results on mRNA-4359 Plus Pembrolizumab in Checkpoint Inhibitor-Resistant Melanoma

Reuters
·
Oct 17

Moderna Inc. Stock Advances 5.5%, Outperforms Peers

Dow Jones
·
Oct 16